98%
921
2 minutes
20
In early Alzheimer's disease (AD) β-amyloid (Aβ) deposits throughout association cortex and tau appears in the entorhinal cortex (EC). Why these initially appear in disparate locations is not understood. Using task-based fMRI and multimodal PET imaging, we assess the impact of local AD pathology on network-to-network interactions. We show that AD pathologies flip interactions between the default mode network (DMN) and the medial temporal lobe (MTL) from inhibitory to excitatory. The DMN is hyperexcited with increasing levels of Aβ, which drives hyperexcitability within the MTL and this directed hyperexcitation of the MTL by the DMN predicts the rate of tau accumulation within the EC. Our results support a model whereby Aβ induces disruptions to local excitatory-inhibitory balance in the DMN, driving hyperexcitability in the MTL, leading to tau accumulation. We propose that Aβ-induced disruptions to excitatory-inhibitory balance is a candidate causal route between Aβ and remote EC-tau accumulation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10922797 | PMC |
http://dx.doi.org/10.1016/j.neuron.2023.11.014 | DOI Listing |
Biomed Pharmacother
September 2025
Department of Biomedical Sciences, Institute of Health, Jimma University, Jimma 378, Ethiopia; Division of Research & Development, Lovely Professional University, Phagwara 144411, India. Electronic address:
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by cognitive decline and the accumulation of misfolded proteins, including amyloid-beta and hyperphosphorylated tau, which impair neuronal function and promote cell death. These misfolded proteins disrupt proteostasis by forming toxic aggregates that exacerbate disease progression. Molecular chaperones, such as heat shock proteins, actively maintain protein homeostasis by assisting in proper folding, preventing aggregation, and promoting the clearance of misfolded proteins.
View Article and Find Full Text PDFExp Neurol
September 2025
Division of Pharmacology and Pharmacotherapy, Drug Research Programme, Faculty of Pharmacy, University of Helsinki, Finland; Department of Pharmacology, Faculty of Medicine, University of Helsinki, Finland. Electronic address:
Traumatic brain injury (TBI) impacts up to 60 million people annually. Both severe TBIs and repeated mild TBIs (rmTBIs) can lead to persistent symptoms such as cognitive deficits, and even neurodegenerative diseases like chronic traumatic encephalopathy (CTE). To date, no therapies exist to mitigate the risk of CTE or other chronic symptoms post-TBI.
View Article and Find Full Text PDFJ Integr Neurosci
August 2025
CIBA Center for Advanced Biomedical Research, School of Medicine, Autonomous University of Queretaro, 76010 Querétaro, México.
Background: Neurofibrillary tangles, composed of hyperphosphorylated tau, have been implicated in the cognitive impairments observed in Alzheimer's disease. While the precise mechanism remains elusive, cognitive deficits in Alzheimer's disease have been associated with disrupted brain network activity. To investigate this mechanism, researchers have developed several tau transgenic models.
View Article and Find Full Text PDFACS Omega
September 2025
Department of Basic Medical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana 47907, United States.
Alzheimer's disease (AD) and Parkinson's disease (PD) are the most prevalent neurodegenerative disorders characterized by continuous loss of functional neurons. The numbers of AD and PD patients will likely double by 2060 and 2040, reaching 13.9 and 1.
View Article and Find Full Text PDFEur J Med Chem
August 2025
Amity Institute of Pharmacy, Amity University Haryana, 122413, India. Electronic address:
Neurodegenerative diseases (NDs), including Alzheimer's, Huntington's, and Parkinson's disease, are associated with significant declines in cognitive function and mobility. The accumulation of misfolded proteins such as β-amyloid, tau, α-synuclein, and polyglutamates is a key factor in the progression of these conditions. Unfortunately, traditional small-molecule drugs face major obstacles in effectively targeting these proteins.
View Article and Find Full Text PDF